Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Could we see that long-awaited RNS tommorrow morning or Monday that is the key question?
Terrible financial results with a cash placement and the share price plunging to no doubt 15p as it dawns on the market that this is nothing more than another speculative bubble which will burst as reality sets in AGL is a very long way from any form of material commercial success !
I'm expecting an imminent 'sledgehammer' RNS release!
Today's independent audit report firmly puts to bed allegations that SYME is a questionable run business and paves the way for both Neo Bank and Gruppo Banoco BPM to announce immently to their shareholder's commercial deals with SYME to fully roll out WL IM to their corporate clients.
The independent audit report is designed to give clear oversight and transparency over the relevant legal entities and confirms that they align to local regulatory and financial reporting.
The allegations of mispropriety and director duplicity are now firmly put to bed!
Johnson & Johnson...as in Boris Johnson!!
Getting desperate EC...
It will be fine another 10% come tommorrow more jam tommorow promises by Newlandas he mugs punters again!
Doctor the patient isn't quite dead its just been zombified lol!
This is such a basket case zero growth potential a dead duck!
I expect an announcement soon on the back of horrid 2023 results.
Great things to come but we need cash funding to keep the lights on..No doubt with the usual charm and persuasion Newland style to mitigate the inevitable share dilution...The target of trebbling revenues to £6.6m this year I believe was a bridge too far!
EC you're trying way too hard again... 😆 lol!
Fevertreeman
Think you will find those contracts are one off payments.
HoofofHeartAgain
Another spoof account it's infectious!.
Member Since
16th Nov 2020
Joined 3 days earlier than 'ThePhony' what a remarkable coincidence and with 18 posts in 3.5 years!
ThePhony
Member Since
20th Nov 2020
Member fir over 3 5 years with 3 posts you look like a Phony account lol!..🙂
They should make a film call it the 'Wolf of Wall Street' staring Newland and based around how you go about hyping a bio penny stock by luring in punters with stories of untold riches and when you reel them in just let slip that to get to that promised land of milk and honey you just need another £20m in donations...I can tell you now that would be a great film plot!
.....🎈📌......Jan, March, now May....!!
85% down on trebling revenues required to extend cash runway to Q2 2025...
Great RNS with little on the way of credible financial numbers, just a few hundred thousand not £6m needed...
All designed to prep the ground with an imminent cash placement with over egged ramping ramping RNS's...with a placement and at what price 12p 15p...?
Seems all the rampers have moved on now...bubble burst share price heading back to 12p.....£22m cash June 2022 down to what maybe £7m and the 2023 financial results?.....
And then tommorrow EC lets slip he's dumped most of his trades..lol
Alot of nonsense being spouted by certain day traders.
1. It takes a very, very long time to progress from a few test trials to mainstream commercial testing.
2. Parsortix is only FDA approved for testing 4% of cancers.
3. Cash is running out...
4. Eisai alot was said then when an RNS was relased months ago but silence now...no trading updates for way over six months...
My view the 2023 financials will be diasterous and AGL are already nearly halfway through the current financial year and 85% down on the target of trebling revenues to £6m in order to reach cash breakeven next year...
I guess there is only around £6m or £7m cash remaining taking the business to December at best.
A cash placement seems highly likely at around 12p hence the RNS's with miniscule financials and all of which takes a long time to get any commercial traction given the very lengthy test regimes third parties need to adhere to and the lack of Parsortix FDA approval for testing a much wider range of cancers.
The much hyped RNS's are really prepping the ground for a heavily discounted placement on the very near future IMHO.
EC
I am not sure if there are any shorts on this position but stand corrected if products are now available.
Only need another £5m+...